Protalix BioTherapeutics, Inc.

Equities

PLX

US74365A3095

Biotechnology & Medical Research

Delayed Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.26 USD +0.80% Intraday chart for Protalix BioTherapeutics, Inc. -4.55% -29.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Protalix BioTherapeutics, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M MT
HC Wainwright Adjusts Protalix BioTherapeutics' Price Target to $10 From $7, Keeps Buy Rating MT
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023 CI
Transcript : Protalix BioTherapeutics, Inc., Q2 2023 Earnings Call, Aug 07, 2023
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q2 Revenue $35.1M MT
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Protalix BioTherapeutics, Inc. - Special Call
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Comp Value Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2500 Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000E Value Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Completeness Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000 Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Dynamic Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000E Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000 Value Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2500 Value Index CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Value Index CI
Protalix BioTherapeutics Eligible for $20 Million Milestone Payment DJ
Protalix Biotherapeutics, Inc. Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases CI
Protalix BioTherapeutics, Chiesi Global Get FDA Approval for Elfabrio DJ
Chart Protalix BioTherapeutics, Inc.
More charts
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company's ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.26 USD
Average target price
13 USD
Spread / Average Target
+931.75%
Consensus
  1. Stock
  2. Equities
  3. Stock Protalix BioTherapeutics, Inc. - Nyse
  4. News Protalix BioTherapeutics, Inc.
  5. Protalix BioTherapeutics : Significant Insider Selling in Shares of Protalix Bio Therapeutics